Real-Life-Setting Effectiveness of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: The Remix Study

被引：2
|
作者：
Clement-Filliatre, Lauriane
Benboubker, Lotfi
Stoppa, Anne-Marie
Rodon, Philippe
Laribi, Kamel
Vincent, Laure
Collet, Philippe
Richez, Valentine
Charvet-Rumpler, Anne
Zerazhi, Hacene
Hulin, Cyrille
Maloisel, Frederic
Macro, Margaret
Karlin, Lionel
Texier, Nathalie
Chouaid, Christos
Leleu, Xavier
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-133807
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in a Real-Life Population in France: The Remix Study
    Vincent, Laure
    Charvet-Rumpler, Anne
    Benboubker, Lotfi
    Calmettes, Claire
    Stoppa, Anne-Marie
    Laribi, Kamel
    Filliatre, Lauriane Clement
    Honeyman, Fressia
    Valentine, Richez
    Hulin, Cyrille
    Maloisel, Frederic
    Macro, Margaret
    Karlin, Lionel
    Barue, Vanessa
    Chouaid, Christos
    Zerazhi, Hacene
    Leleu, Xavier
    BLOOD, 2022, 140 : 4312 - 4314
  • [2] Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study
    M. Macro
    C. Hulin
    L. Vincent
    A. Charvet-Rumpler
    L. Benboubker
    C. Calmettes
    A.-M. Stoppa
    K. Laribi
    L. Clement-Filliatre
    H. Zerazhi
    F. Honeyman
    V. Richez
    F. Maloisel
    L. Karlin
    J. Barrak
    C. Chouaid
    X. Leleu
    Annals of Hematology, 2023, 102 : 2137 - 2151
  • [3] Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study
    Macro, M.
    Hulin, C.
    Vincent, L.
    Charvet-Rumpler, A.
    Benboubker, L.
    Calmettes, C.
    Stoppa, A. -m.
    Laribi, K.
    Clement-Filliatre, L.
    Zerazhi, H.
    Honeyman, F.
    Richez, V.
    Maloisel, F.
    Karlin, L.
    Barrak, J.
    Chouaid, C.
    Leleu, X.
    ANNALS OF HEMATOLOGY, 2023, 102 (08) : 2137 - 2151
  • [4] Real-world effectiveness of ixazomib, lenalidomide and dexamethasone in Asians with relapsed/refractory multiple myeloma
    Soo Chin Ng
    Joon-Ho Moon
    Sung Soo Park
    Youngil Koh
    Ji Hyun Lee
    Hyeon-Seok Eom
    Ho-Jin Shin
    Sung Hoon Jung
    Young Rok Do
    Gilbert Wilfred
    Azlan Husin
    Hyo Jung Kim
    SFadilah Abdul Wahid
    Myung-Won Lee
    Hye-won Heo
    Kihyun Kim
    Suporn Chuncharunee
    International Journal of Hematology, 2025, 121 (5) : 670 - 683
  • [5] Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
    Terpos, Evangelos
    Ramasamy, Karthik
    Maouche, Nadjoua
    Minarik, Jiri
    Ntanasis-Stathopoulos, Ioannis
    Katodritou, Eirini
    Jenner, Matthew W.
    Plonkova, Hana
    Gavriatopoulou, Maria
    Vallance, Grant D.
    Pika, Tomas
    Kotsopoulou, Maria
    Kothari, Jaimal
    Jelinek, Tomas
    Kastritis, Efstathios
    Aitchison, Robin
    Dimopoulos, Meletios A.
    Zomas, Athanasios
    Hajek, Roman
    ANNALS OF HEMATOLOGY, 2020, 99 (05) : 1049 - 1061
  • [6] Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
    Evangelos Terpos
    Karthik Ramasamy
    Nadjoua Maouche
    Jiri Minarik
    Ioannis Ntanasis-Stathopoulos
    Eirini Katodritou
    Matthew W. Jenner
    Hana Plonkova
    Maria Gavriatopoulou
    Grant D. Vallance
    Tomas Pika
    Maria Kotsopoulou
    Jaimal Kothari
    Tomas Jelinek
    Efstathios Kastritis
    Robin Aitchison
    Meletios A. Dimopoulos
    Athanasios Zomas
    Roman Hajek
    Annals of Hematology, 2020, 99 : 1049 - 1061
  • [7] REAL WORLD USE OF IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED REFRACTORY MULTIPLE MYELOMA
    Ziff, M.
    Cheesman, S.
    Kyriakou, C.
    Mehta, A.
    Papanikolaou, X.
    Rabin, N.
    Wechalekar, A.
    Yong, K.
    Popat, R.
    HAEMATOLOGICA, 2017, 102 : 786 - 787
  • [8] BUDGET IMPACT OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN RUSSIA
    Pyadushkina, E.
    Derkach, E., V
    Boyarskaya, T.
    VALUE IN HEALTH, 2018, 21 : S26 - S26
  • [9] BUDGET IMPACT OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN BRAZIL
    Sakagute, M.
    Tanaka, P. Y.
    Duva, A.
    Rigolon, J.
    VALUE IN HEALTH, 2019, 22 : S459 - S459
  • [10] Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma
    Minarik, Jiri
    Pika, Tomas
    Radocha, Jakub
    Jungova, Alexandra
    Straub, Jan
    Jelinek, Tomas
    Pour, Ludek
    Pavlicek, Petr
    Mistrik, Martin
    Brozova, Lucie
    Krhovska, Petra
    Machalkova, Katerina
    Jindra, Pavel
    Spicka, Ivan
    Plonkova, Hana
    Stork, Martin
    Bacovsky, Jaroslav
    Capkova, Lenka
    Sykora, Michal
    Kessler, Petr
    Stejskal, Lukas
    Heindorfer, Adriana
    Ullrychova, Jana
    Maisnar, Vladimir
    Hajek, Roman
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E271 - E272
12345